Compare Enveric Biosciences Inc (ENVB) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs SYSCO Corporation — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while SYSCO Corporation trades at $78.12 (market cap $38.47B). The key difference: SYSCO Corporation is far larger — about 5657.4× Enveric Biosciences Inc's market cap, and SYSCO Corporation pays a 2.81% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and SYSCO Corporation for 77 Days on average.
| ENVB | SYY | |
|---|---|---|
Market Cap | $6.80M | $38.47B |
Volume | 64,867 | 4,808,465 |
Sector | Health | Consumer Staples |
52-Week High | $10.80 | $91.16 |
52-Week Low | $1.27 | $69.30 |
Typical Hold Time | 14 Days | 77 Days |
Enterprise Value | -$1.49M | $51.65B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Sysco Corporation (SYY) trades at $76.79, down 0.85% with a bearish technical outlook. The company shows solid revenue growth to $81.37B in 2025 but faces margin compression with net income margin at 2.08%. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, representing 11.7% upside potential.
SYY offers value with a P/S ratio of 0.44x and dividend yield support, but faces execution risks on margin improvement and debt management. The stock trades below analyst targets, providing potential upside if the company delivers on its AI efficiency goals and maintains market leadership in food distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
